Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients

The DR-70® (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared for 113 CRC monitoring patients. Tota...

Descripción completa

Detalles Bibliográficos
Autores principales: Small-Howard, Andrea L., Harris, Holden
Formato: Texto
Lenguaje:English
Publicado: Taylor & Francis 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872273/
https://www.ncbi.nlm.nih.gov/pubmed/20391025
http://dx.doi.org/10.1080/15321811003617438
Descripción
Sumario:The DR-70® (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared for 113 CRC monitoring patients. Total concordance rates for DR-70 and CEA were 0.665 and 0.686, respectively. CRC patient pairs were grouped based on their CEA value to deduce DR-70's effectiveness at monitoring patients with low CEA values. DR-70 had 12% to 100% greater positive concordance rates than CEA in this group. DR-70 is a welcome new option for CRC patients.

Ejemplares similares